1 Quantification of circulating miR-125b-5p predicts survival in chronic hepatitis B patients with acute-on-chronic liver failure.

2 real-time tissue elastography in the evaluation of liver cirrhosis in patients with chronic hepatitis b

3 effectiveness of entecavir treatment and predictive factors for virologic response

4 tlr2 expression in peripheral cd4+ t cells promotes th17 response and is associated with disease aggravation of hepatitis b virus-related acute-on-chronic liver failure

5 static and dynamic prognostic factors for hepatitis-b-related acute-on-chronic liver failure

6 efficacy of switching from adefovir to tenofovir in chronic hepatitis b patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (satis study)

7 comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment

8 correlation between two chemiluminescence based assays for quantification of hepatitis b surface antigen in patients with chronic hepatitis b infection

9 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

10 Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

11 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

12 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

13 Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

14 Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

15 Safety and efficacy of entecavir for the treatment of chronic hepatitis B

16 New approaches in the management of chronic hepatitis B: role of tenofovir

17 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

18 Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

19 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

20 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

21 Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

22 Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

23 Safety and efficacy of entecavir for the treatment of chronic hepatitis B

24 New approaches in the management of chronic hepatitis B: role of tenofovir

25 Clinical factors leading to a change in management in chronic hepatitis B patients managed in a tertiary setting.

26 High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation

27 Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: An open-label, randomized, controlled study

28 Electronic health informatics data to describe clearance dynamics of hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) in chronic hepatitis B virus infection

29 Title: p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B.

30 Correlation of CpG methylation of Pdcd1 gene with PD-1 expression on CD8 T cells and medical laboratory indicators in chronic hepatitis B infection.

31 Metabolomics analysis of the saliva in patients with chronic hepatitis B using nuclear magnetic resonance: a pilot study.

32 Evaluation of the /S Gene Overlapping Mutations in Chronic Hepatitis B Patients in Northern Cyprus.

33 The diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients

34 Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.

35 Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.

36 Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection

37 relationship between hbv dna and hbeag in serum and hbcag and inflammation grade in liver tissue among patients with chronic hepatitis b

38 comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis b

39 intravenous glycyrrhizin improved serum transaminases rapidly in a chronic hepatitis b patient with acute exacerbation

40 primary hepatic small-cell carcinoma developed during antiviral treatment for chronic hepatitis b

41 pnpla3 rs1010023 predisposes chronic hepatitis b to hepatic steatosis but improves insulin resistance and glucose metabolism

42 research advances in drug resistance to nucleos(t)ide analogues in treatment of chronic hepatitis b

43 effects of nucleos(t)ide analogues on estimated glomerular filtration rate and serum creatinine level in patients with chronic hepatitis b

44 lamivudine for the treatment of membranous glomerulopathy secondary to chronic hepatitis b infection

45 effect of entecavir combined with fuzheng huayu capsules on inflammatory factors and fibrosis markers in patients with compensated chronic hepatitis b-related cirrhosis

46 hbv genotype distribution and its relationship with serum hbv dna level and hbeag expression among patients with chronic hepatitis b in southern zhejiang province, china

47 comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis b

48 molecular mechanisms of same tcm syndrome for different diseases and different tcm syndrome for same disease in chronic hepatitis b and liver cirrhosis

49 a noninvasive score model for prediction of nash in patients with chronic hepatitis b and nonalcoholic fatty liver disease

50 spanish multicentre pibhe study: prevalence and immunisation of chronic hepatitis b in haemodialysis patients in spain

51 a better antiviral efficacy found in nucleos(t)ide analog (na) combinations with interferon therapy than na monotherapy for hbeag positive chronic hepatitis b: a meta-analysis

52 acute exacerbation in chronic hepatitis b virus infection

53 research progress in metabolic activity of natural killer cells in patients with chronic hepatitis b virus infection

54 count of peripheral blood dendritic cells and its clinical significance in patients with acute-on-chronic hepatitis b liver failure

55 the efficacy of lamivudine in the treatment of reactivation of chronic hepatitis b virus infection in patients on immunosuppressive therapy

56 gamma-glutamyl transpeptidase-to-platelet ratio predicts significant liver fibrosis of chronic hepatitis b patients in china

57 clinical trial of telbivudine in the treatment of chronic hepatitis b in patients during the third trimester of pregnancy

58 association of interleukin-27 gene rs153109 polymorphism and chronic hepatitis b infection

59 antiviral therapy against chronic hepatitis b in brazil: high rates of lamivudine resistance mutations and correlation with hbv genotypes

60 pursue excellence of clinical research on chronic hepatitis b in china

61 comparison of fibrotest-actitest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis b and c

62 hepatic expression of cannabinoid receptors cb1 and cb2 correlate with fibrogenesis in patients with chronic hepatitis b

63 surface protein mutations in chronic hepatitis b patients who received hepatitis b vaccine therapy

64 antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis b virus infected patients

65 seroprevalence of chronic hepatitis b, as determined from dried blood spots, among children and their mothers in central lao people's democratic republic: a multistage, stratified cluster sampling survey

66 chronic hepatitis b in canada

67 efficacy of tenofovir-based rescue therapy for chronic hepatitis b patients with resistance to lamivudine and entecavir

68 hepatitis b virus-related glomerulonephritis: not a predominant cause of proteinuria in korean patients with chronic hepatitis b

69 antineutrophil cytoplasmic antibody frequency in chronic hepatitis b patients

70 hepatitis b virus surface antigen variants clustered within immune epitopes in chronic hepatitis b carriers from hormozgan province, south of iran

71 clinical utility of entecavir for chronic hepatitis b in chinese patients

72 Virus and Host Testing to Manage Chronic Hepatitis B

73 The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen–Seropositive Children

74 Clinical Predictors of Liver Fibrosis in Patients With Chronic Hepatitis B Virus Infection From Children to Adults

75 Eradication Strategies for Chronic Hepatitis B Infection

76 Chronic hepatitis B

77 Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B

78 Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc

79 Pre-existing mutations in reverse transcriptase of hepatitis B virus in treatment-naive Chinese patients with chronic hepatitis B.

Keyword Connections

Journals

Research Groups

Bibliographies